

Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non–Clear Cell Renal Cell Carcinoma



Andrew J. Armstrong, Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian K. Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa M. Pickering, Christopher W. Ryan, Andrew Protheroe, Daniel J. George, and Susan Halabi

In earlier versions of this article (1) that were published online on February 16, 2021 and March 23, 2021, three errors were made during analysis of the angiokines dataset. First, 89 patients were reported in the article, and the correct sample size was 99 patients. Second, there was a variable labeling error for the censoring indicator for the overall survival endpoint. Third, an incorrect censoring indicator for the progression-free survival endpoint was utilized. To help address these errors, the authors reanalyzed the data and added a new author to their article: Qian Yang. Although these errors changed the figures in the tables and the graphs, the updated analysis did not change the overall scope/findings or the conclusions. All stated errors have been corrected in the text, figures, and tables in the printed version of the article and in the latest online HTML and PDF versions. The authors regret these errors.

Reference

1. Armstrong AJ, Nixon AB, Carmack A, Yang Q, Eisen T, Stadler WM, et al. Angiokines associated with outcomes after sunitinib or everolimus treatment in patients with non–clear cell renal cell carcinoma. *Clin Cancer Res* 2021;27:3317–28.

Published online June 11, 2021.
Clin Cancer Res 2021;27:3503
doi: 10.1158/1078-0432.CCR-21-1636
©2021 American Association for Cancer Research.